Portal de Periódicos da CAPES

Mutant p53 cooperates with ETS2 to promote etoposide resistance

2012; Cold Spring Harbor Laboratory Press; Volume: 26; Issue: 8 Linguagem: Inglês

10.1101/gad.181685.111

1549-5477

Phi M., Lakshman Varanasi, Songqing Fan, Chunyang Li, Iwona Kubacka, Virginia Newman, Krishna M. Chauhan, Silvano Rakeem Daniels, Maurizio Boccetta, Michael R. Garrett, Runzhao Li, Luis A. Martinez,

Peptidase Inhibition and Analysis

Mutant p53 (mtp53) promotes chemotherapy resistance through multiple mechanisms, including disabling proapoptotic proteins and regulating gene expression. Comparison of genome wide analysis of mtp53 binding revealed that the ETS-binding site motif (EBS) is prevalent within predicted mtp53-binding sites. We demonstrate that mtp53 regulates gene expression through EBS in promoters and that ETS2 mediates the interaction with this motif. Importantly, we identified TDP2, a 5′-tyrosyl DNA phosphodiesterase involved in the repair of DNA damage caused by etoposide, as a transcriptional target of mtp53. We demonstrate that suppression of TDP2 sensitizes mtp53-expressing cells to etoposide and that mtp53 and TDP2 are frequently overexpressed in human lung cancer; thus, our analysis identifies a potentially “druggable” component of mtp53's gain-of-function activity.